secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001326190-23-000017
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports positive Week 24 interim data from Phase 2 obesity trial; pemvidutide up to 10.7% mean weight loss
--------------------------------------------------------------------------------

- Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24; p < 0.001 vs placebo.
- In subjects ≤115 kg baseline (75% of cohort), mean weight loss reached 11.9% at 2.4 mg dose.
- ~50% achieved ≥10% weight loss and ~20% achieved ≥15% at 1.8 mg and 2.4 mg doses.
- Phase 1b diabetes trial: 7.7% mean weight loss at 2.4 mg dose; no SAEs or discontinuations.
- GI AEs mostly mild/moderate; lower doses used without titration; one SAE at 2.4 mg (nausea/vomiting).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000017/0001326190-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000017/alt-20230321x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer